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Figure 1. Effect of Montelukast treatment on Mean Maximal Knee OA Score (±
SEM).
Figure 2. Effect of Montelukast treatment on Mean Summed Knee OA Score (±
SEM).
Figure 3. Reversal of sclerotic changes in subchondral bone with Montelukast
(MKS) treatment. *p-value <0.005, **p-value <0.05.
indirect effect of decreased cartilage damage on aberrant bone re-
modeling.
Conclusions: The dual goals of translation research are to dis-
cover novel disease mechanisms and to transform this informa-
tion into new therapeutics for human disorders. Here we present
data that implicate cysteinyl leukotrienes in early OA progression.
Therefore, targeting of this pathway could represent an important
area to OA research and treatment. In addition, the apparent
similarities of the DMM model to humans at risk for OA from
meniscal damage, suggests that treatment proximal to the time
of meniscal repair with CysLT antagonists could delay the struc-
tural progression of incipient OA. Subchondral bony sclerosis is a
contributing co-factor in OA progression. Although, the reduction
in cartilage damage observed in this study could be seen as
the most clinically relevant outcome for montelukast treatment of
OA, prevention of abnormal bone remodeling could have equally
important outcomes in OA joint prophylaxis.
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Purpose: There is increasing evidence that subchondral bone
remodeling may contribute to the pathogenesis of OA, in both dis-
ease initiation and progression. In this study, we investigated the
potential role of cathepsin K (CatK) as a disease-modifying target
in the rabbit anterior cruciate ligament transection (ACLT) model
of osteoarthritis. To test the hypothesis, we evaluated the dis-
ease modifying effects of two different bone resorption inhibitors,
L-006235, a potent inhibitor of Cat K, and compared to the bis-
phosphonate Alendronate (ALN), on subchondral bone integrity,
cartilage degradation, and osteophyte formation in the rabbit ACLT
model.
Methods: Male NZW rabbits (N= 35) underwent anterior cruci-
ate ligament transection (ACLT) or sham-operation in the right
knee. The animals were dosed at one-week post-surgery with
either the CatK inhibitor L-235 (10 or 50mg/kg, p.o., daily) or ALN
(0.6mg/kg/wk, s.c.) for 8 weeks treatment duration. Rabbits were
randomized and assigned into 5 groups: Sham + vehicle (V); ACLT
+ V; ACLT + ALN; ACLT + 10mg/kg L-235; ACLT + 50mg/kg L-235.
Disease progression was evaluated by modiﬁed Mankin score.
Subchondral bone volume and osteophyte area were measured
by histomorphometric analysis. Urine levels of helical peptide, a
marker for bone resorption and CTX-II, a cartilage degradation
marker were measured at 3, 5, and 7 wk-post-surgery. Immunos-
taining of CatK and TRAP staining was performed to identify cells
expressing CatK protein and osteoclasts, respectively.
Results: In the ACLT-rabbits, CatK is highly expressed in osteo-
clasts localized to the subchondral bone region of the affected
joints. CatK expression is also found to be elevated in synovial
ﬁbroblasts, macrophages, and cells in the superﬁcial region of ar-
ticular cartilage. In addition to mediating bone matrix degradation,
detection of high CatK expression in other cell types suggests that
it may also be directly responsible for cartilage ECM degradation.
Moreover, subchondral bone resorption in the tibial plateau was
signiﬁcantly increased in the ACLT-joints at 5-wk post-surgery.
Treatment with either dose of L-235 or with ALN for 8-weeks
effectively suppressed subchondral bone loss in the ACLT-joints.
Furthermore, L-235 dose-dependently reduced osteophyte inci-
dence and area. The CatK inhibitor and ALN were partially chon-
droprotective as determined by histological evaluation and type II
collagen degradation marker. L-235 at 10mg/kg, were previously
demonstrated to fully protect estrogen-deﬁciency induced bone
loss in rabbits. While this dose of L-235 provided no chondropro-
tective effects as determined by Mankin score, 50mg/kg L-235 and
ALN provided 48% (p<0.001) and 46% (p<0.001) chondroprotec-
tion, respectively. L-235 and ALN both inhibited osteophyte forma-
tion by 56% (p<0.001) and 38% (p<0.001), respectively. TRAP
staining multinuclear cells were positive for CatK immunostaining,
and these cells were observed in subchondral region of ACLT
joint. Interestingly, in L-235-treated joint, TRAP(+) cells were small
and number of nuclei was low.
Conclusions: Taken together, the data from this study support the
important role of subchondral bone remodeling in the pathogenesis
of OA in preclinical models. Furthermore, an oral, potent and
selective CatK inhibitor may present an effective disease modifying
therapy for the treatment of osteoarthritis.
